Fosamax Osteonecrosis of the Jaw Settlement: Understanding New Jersey's Statute of Limitations

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medication safety and long-term treatment outcomes. In this context, patients and healthcare providers have relied on broad educational resources to navigate the benefits and risks associated with prescription drugs. Among the many medications subject to such scrutiny, bisphosphonates like Fosamax have been widely prescribed for bone density management, with their safety profiles communicated through standard health channels. As awareness of adverse effects has evolved, a specific concern has emerged regarding the potential for osteonecrosis of the jaw—a condition involving bone tissue death in the jaw—linked to prolonged Fosamax exposure. This transition from general health guidance to a focused occupational exposure concern is particularly relevant for individuals who have taken the medication over extended periods. In New Jersey, legal frameworks address the statute of limitations for filing claims related to such injuries, requiring affected parties to understand both the medical timeline and the legal deadlines. The shift from broad health literacy to targeted risk awareness underscores the need for precise information on exposure duration, symptom onset, and jurisdictional requirements.

​

Medical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Onset of Fosamax-Related Jaw Complications

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption, which can suppress normal bone turnover. This suppression, particularly in the jawbone, may impair the ability to repair microdamage and respond to local stressors such as dental procedures or infection. Current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the clinical presentation of ONJ can be variable, and the timeline between exposure to Fosamax and documented harm can range from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Statute of Limitations for Fosamax Claims in New Jersey

Settlement-related considerations for affected patients in New Jersey involve the statute of limitations, which is the time limit within which a lawsuit must be filed. In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For patients who developed ONJ after taking Fosamax, the clock typically starts when the patient knew or should have known that the injury was caused by the drug. Given that the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), patients must be vigilant about recognizing symptoms such as jaw pain, swelling, or non-healing extraction sites. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so patients who have taken Fosamax for extended periods should be particularly aware of potential jaw-related issues. In summary, the medical evidence establishes a clear link between Fosamax use and the development of ONJ, with specific risk factors and variable onset times. The prescribing information includes warnings about this risk, but patients who have suffered harm may need to consider legal action within the applicable statute of limitations in New Jersey. Settlement considerations should account for the adequacy of warnings, the timeline between exposure and harm, and the individual patient's circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Time is limited. Request your evaluation today.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Check My Eligibility Now

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For osteonecrosis of the jaw (ONJ), the clock typically starts when the patient knew or should have known that the injury was caused by Fosamax.

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients should be vigilant for symptoms such as jaw pain, swelling, or non-healing extraction sites, especially if they have taken the drug for extended periods.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Does Fosamax cause Osteonecrosis of the Jaw
• Statute of limitations for Fosamax in Massachusetts
• Long term outcome of Osteonecrosis of the Jaw after Fosamax
• Ohio Fosamax Osteonecrosis of the Jaw injury lawyer
• Statute of limitations for Fosamax in New York

References

1. Fosamax Prescribing Information (DailyMed)
2. Fosamax Warnings and Precautions (DailyMed)
3. Multiscale Characterization of Jawbone (PubMed)

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.